RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BARD1 Life Sciences Stock

BARD1 Life Sciences ROE 2024

BARD1 Life Sciences ROE

-0.38

Ticker

BD1.AX

ISIN

AU000000BD12

WKN

A2AL50

In 2024, BARD1 Life Sciences's return on equity (ROE) was -0.38, a 0% increase from the 0 ROE in the previous year.

BARD1 Life Sciences Aktienanalyse

What does BARD1 Life Sciences do?

BARD1 Life Sciences Ltd. is an Australian biotechnology company specializing in the development of diagnostics and therapeutics for cancer. The company was founded in 1999 and is headquartered in Sydney. BARD1 Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding BARD1 Life Sciences's Return on Equity (ROE)

BARD1 Life Sciences's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing BARD1 Life Sciences's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

BARD1 Life Sciences's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in BARD1 Life Sciences’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about BARD1 Life Sciences stock

What is the ROE (Return on Equity) of BARD1 Life Sciences this year?

The ROE of BARD1 Life Sciences this year is -0.38 undefined.

How has the Return on Equity (ROE) of BARD1 Life Sciences developed compared to the previous year?

The ROE of BARD1 Life Sciences has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of BARD1 Life Sciences?

A high ROE indicates that BARD1 Life Sciences generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of BARD1 Life Sciences?

A low ROE can indicate that BARD1 Life Sciences is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of BARD1 Life Sciences affect the company?

A change in ROE (Return on Equity) of BARD1 Life Sciences can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of BARD1 Life Sciences?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of BARD1 Life Sciences?

Some factors that can influence BARD1 Life Sciences's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does BARD1 Life Sciences pay?

Over the past 12 months, BARD1 Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BARD1 Life Sciences is expected to pay a dividend of 0 AUD.

What is the dividend yield of BARD1 Life Sciences?

The current dividend yield of BARD1 Life Sciences is .

When does BARD1 Life Sciences pay dividends?

BARD1 Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BARD1 Life Sciences?

BARD1 Life Sciences paid dividends every year for the past 0 years.

What is the dividend of BARD1 Life Sciences?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BARD1 Life Sciences located?

BARD1 Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von BARD1 Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BARD1 Life Sciences from 12/3/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 12/3/2024.

When did BARD1 Life Sciences pay the last dividend?

The last dividend was paid out on 12/3/2024.

What was the dividend of BARD1 Life Sciences in the year 2023?

In the year 2023, BARD1 Life Sciences distributed 0 AUD as dividends.

In which currency does BARD1 Life Sciences pay out the dividend?

The dividends of BARD1 Life Sciences are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BARD1 Life Sciences

Our stock analysis for BARD1 Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BARD1 Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.